近年来关于铋化合物在癌症化疗和放疗中的研究趋势。

Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy.

机构信息

Institute of Chemistry, Jan Kochanowski University in Kielce, Kielce, Poland.

出版信息

Curr Med Chem. 2019;26(4):729-759. doi: 10.2174/0929867324666171003113540.

DOI:10.2174/0929867324666171003113540

PMID:28971764

Abstract

BACKGROUND

Application of coordination chemistry in nanotechnology is a rapidly developing research field in medicine. Bismuth complexes have been widely used in biomedicine with satisfactory therapeutic effects, mostly in Helicobacter pylori eradication, but also as potential antimicrobial and anti-leishmanial agents. Additionally, in recent years, application of bismuth-based compounds as potent anticancer drugs has been studied extensively.

METHODS

Search for data connected with recent trends on bismuth compounds in cancer chemo- and radiotherapy was carried out using web-based literature searching tools such as ScienceDirect, Springer, Royal Society of Chemistry, American Chemical Society and Wiley. Pertinent literature is covered up to 2016.

RESULTS

In this review, based on 213 papers, we highlighted a number of current problems connected with: (i) characterization of bismuth complexes with selected thiosemicarbazone, hydrazone, and dithiocarbamate classes of ligands as potential chemotherapeutics. Literature results derived from 50 papers show that almost all bismuth compounds inhibit growth and proliferation of breast, colon, ovarian, lung, and other tumours; (ii) pioneering research on application of bismuth-based nanoparticles and nanodots for radiosensitization. Results show great promise for improvement in therapeutic efficacy of ionizing radiation in advanced radiotherapy (described in 36 papers); and (iii) research challenges in using bismuth radionuclides in targeted radioimmunotherapy, connected with choice of adequate radionuclide, targeting vector, proper bifunctional ligand and problems with 213Bi recoil daughters toxicity (derived from 92 papers).

CONCLUSION

This review presents recent research trends on bismuth compounds in cancer chemo- and radiotherapy, suggesting directions for future research.

摘要

背景

配位化学在纳米技术中的应用是医学领域中一个快速发展的研究领域。铋配合物在生物医学中得到了广泛的应用，具有令人满意的治疗效果，主要用于幽门螺杆菌的根除，但也可用作潜在的抗菌和抗利什曼原虫药物。此外，近年来，人们广泛研究了将基于铋的化合物用作有效的抗癌药物。

方法

使用基于网络的文献搜索工具，如 ScienceDirect、Springer、皇家化学学会、美国化学学会和 Wiley 等，搜索与癌症化疗和放疗中铋化合物的最新趋势相关的数据。涵盖的相关文献截止到 2016 年。

结果

在本综述中，基于 213 篇论文，我们强调了与以下几个方面相关的一些当前问题：（i）具有选定的硫代半卡巴腙、腙和二硫代氨基甲酸盐类配体的铋配合物的特征化作为潜在化疗药物。来自 50 篇论文的文献结果表明，几乎所有的铋化合物都能抑制乳腺癌、结肠癌、卵巢癌、肺癌和其他肿瘤的生长和增殖；（ii）应用基于铋的纳米粒子和纳米点进行放射增敏的开创性研究。结果表明，在先进的放疗中，改善电离辐射的治疗效果具有很大的潜力（在 36 篇论文中描述）；（iii）在靶向放射免疫治疗中使用放射性铋核素的研究挑战，与选择适当的放射性核素、靶向载体、合适的双功能配体以及 213Bi 反冲子毒性的问题有关（来自 92 篇论文）。